2017 was a fascinating year for those of us closely following the clinical research industry. And 2018 promises not to disappoint.
Within the WIRB-Copernicus Group (WCG) family of companies, our subject matter experts are always watching regulatory, technology, and practice trends. Their observations, combined with a deep understanding of the science and practice of clinical research, provide the basis for our strategic planning. In this way, we support both our biopharma partners and our institutional partners to be prepared for not only what is currently happening in clinical research, but what is likely to happen in the future.
In this paper, some of our thought-leaders provide their insights on what they are watching for and what they anticipate in 2018 in clinical trial technology, regulatory changes, and scientific developments.
About the Author
Dr. Lindsay McNair has extensive experience in the pharmaceutical industry. Prior to joining WCG, she was a consultant to pharmaceutical and biotechnology companies, providing medical guidance on clinical development strategies and study designs for new drug studies, and medical oversight of all phases of clinical trials. Dr. McNair teaches graduate-level courses on the scientific design of clinical research studies. She has been actively involved in IRB work for 18 years, and has a Master’s of Science in Bioethics with a concentration in research ethics.Follow on Twitter More Content by Dr. Lindsay McNair, MD, MPH, MSB | Chief Medical Officer, WCG